Jade Biosciences Financial Statements
NASDAQ: JBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
14.39+0.24 (+1.70%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Jade Biosciences revenue and earnings
Jade Biosciences reported a net loss of $127.4 million, compared with a loss of $69.6 million a year earlier. Diluted earnings per share came in at -$3.19.
Summary generated from market data by MetaCap's automated system. Methodology
Jade Biosciences income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Operating Expenses | 113.54M | 74.60M | 81.41M | 53.24M | 23.02M | 8.89M |
| Research & Development | 93.12M | 53.19M | 64.22M | 38.62M | 14.99M | 7.94M |
| Operating Income | -113.54M | -74.60M | -81.41M | -53.24M | -23.02M | -8.89M |
| Interest Expense | — | — | — | — | — | 75.00K |
| Other Income (Expense) | -13.81M | 5.02M | 5.94M | 1.75M | 62.00K | -722.00K |
| Pretax Income | -127.35M | -69.57M | -75.47M | -51.49M | -22.96M | -9.61M |
| Income Tax | 58.00K | 55.00K | 56.00K | 25.00K | 3.00K | — |
| Net Income | -127.41M | -69.63M | -75.52M | -51.51M | -22.96M | -9.61M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| EPS (Basic) | -3.19 | -2.44 | -2.87 | -2.10 | -1.87 | -40.31 |
| EPS (Diluted) | -3.19 | -2.44 | -2.87 | -2.10 | -1.87 | -40.31 |
| Shares Outstanding (Basic) | 31.36M | 28.58M | 26.33M | 24.47M | 12.29M | 242.23K |
| Shares Outstanding (Diluted) | 31.36M | 28.58M | 26.33M | 24.47M | 12.29M | 242.23K |
| EBITDA | -113.52M | -74.31M | -81.31M | -53.17M | -23.01M | -8.89M |
This table shows 6 annual periods of Jade Biosciences's income statement, from FY 2025 back to FY 2020, across 13 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow JBIO's reporting calendar. What is a income statement?